ArticleJournal of viral hepatitis2021

Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.

Sergio Rodríguez-Tajes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.